EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà und 6 weitere

Future Oncology · 2023

DOI: 10.2217/fon-2022-1258 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Future Oncology, 2023. Verfasst von Reinhard Dummer und 17 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WHAT IS THIS SUMMARY ABOUT?: Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma. Encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma. Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group). WHAT WERE THE RESULTS?: In this 5-year update, more participants in the COMBO group were alive for longer without their disease getting worse after 5 years than those in the VEMU and ENCO groups. Patients in the COMBO group were alive for longer without their disease getting worse when they: Had less advanced cancer Were able to do more daily activities Had normal lactate dehydrogenase (LDH) levels Had fewer organs with tumors before treatment After treatment, fewer participants in the COMBO group received additional anticancer treatment than participants in the VEMU and ENCO groups. The number of participants who reported severe side effects was similar for each treatment. The side effects caused by the drugs in the COMBO group decreased over time. WHAT DO THE RESULTS MEAN?: Overall, this 5-year update confirmed that people with BRAF V600-mutant melanoma that has spread to other parts of the body and who took encorafenib plus binimetinib were alive for longer without their disease getting worse than those who took vemurafenib or encorafenib alone. Clinical Trial Registration: NCT01909453 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsMelanomaSkin NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenibBenzimidazolesCarbamatesSulfonamides

Stichwörter der Autor:innen

BRAF V600BRAF inhibitorCOLUMBUSCOLUMBUS part 1MEK inhibitorbinimetinibencorafenibmelanomaplain language summaryvemurafenib

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenibbinimetinibBenzimidazolesBRAF protein, humanencorafenibCarbamatesSulfonamides

Autor:innen und Institutionen

  • University Hospital Zurich, Zurich, Switzerland.
  • Massachusetts General Hospital, Boston, MA, USA.
  • Gustave Roussy & Paris-Saclay University, Villejuif, France.
  • Hospital Clinic of Barcelona & IDIBAPS, Barcelona, Spain.
  • Isala Oncology Center, Zwolle, The Netherlands.
  • University Hospital Tubingen, Tubingen, Germany.

Zitieren

APA

Dummer, R., Flaherty, K. T., Robert, C., Arance, A., B de Groot, J. W., Garbe, C., Gogas, H. J., Gutzmer, R., Krajsová, I., Liszkay, G., Loquai, C., Mandalà, M., Schadendorf, D., Yamazaki, N., Pietro, A. D., Cantey-Kiser, J., Edwards, M., & Ascierto, P. A. (2023). A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma. Future Oncology. https://doi.org/10.2217/fon-2022-1258

Vancouver

Dummer R, Flaherty KT, Robert C, Arance A, B de Groot JW, Garbe C, et al. A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma. Future Oncology. 2023. doi:10.2217/fon-2022-1258

BibTeX
@article{Dummer2023,
  author = {Dummer, Reinhard and Flaherty, Keith T and Robert, Caroline and Arance, Ana and B de Groot, Jan Willem and Garbe, Claus and Gogas, Helen J and Gutzmer, Ralf and Krajsová, Ivana and Liszkay, Gabriella and Loquai, Carmen and Mandalà, Mario and Schadendorf, Dirk and Yamazaki, Naoya and Pietro, Alessandra di and Cantey-Kiser, Jean and Edwards, Michelle and Ascierto, Paolo A},
  title = {A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2022-1258}
}
Kostenlos starten →